Instadose Pharma(INSD)
$0.00+0.00 (+9900.00%)
INSD
Instadose Pharma financials statements
$0.00
At close:+0.00 (+9900.00%)
Instadose Pharma (INSD) Ratios
19 Followers
Instadose Pharma Ratios
INSD's free cash flow for Q1 2022 was $160.44K. For the 2022 fiscal year, INSD's free cash flow was increased by $0.00 and operating cash flow was $160.44K. See a summary of the company’s cash flow.
| Ratios | Nov 21 | Nov 20 | Nov 19 | Nov 18 | Nov 17 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Quick Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Solvency Ratio | -1.79 | -0.07 | -0.43 | -0.70 | -2.44 |
| Operating Cash Flow Ratio | -0.00 | -0.00 | 0.00 | -0.09 | -1.58 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -127.02K | $ -206.71K | $ -106.94K | $ -44.38K | $ -15.48K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 659.54 | 246.51 | 8.51 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | -0.57 | -0.74 | -0.77 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | -1.33 | -2.81 | -3.32 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.02 | -0.00 | -0.00 | -0.00 | -0.09 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -0.42 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.00 | 0.01 | -2.39 | -1.04 | -0.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 49.13% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | -867.03% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | -867.03% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | -653.01% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | -867.03% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | -867.03% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | -867.03% | 0.00% |
| Net Income Per EBT | 127.48% | 129.84% | 165.78% | 100.00% | 100.00% |
| EBT Per EBIT | 100.00% | 100.00% | 100.00% | 132.78% | 128.69% |
| Return on Assets (ROA) | -19633.33% | -39471.34% | -45713.20% | -23540.00% | -2941.71% |
| Return on Equity (ROE) | 463.72% | 31.15% | 39.56% | 70.42% | 265.52% |
| Return on Capital Employed (ROCE) | 372.55% | 12.41% | 30.92% | 53.04% | 206.33% |
| Return on Invested Capital (ROIC) | 372.55% | 12.41% | 118.74% | 53.04% | -752.59% |
| Return on Tangible Assets | -19633.33% | -39471.34% | -45713.20% | -23540.00% | -2941.71% |
| Earnings Yield | -0.03% | -0.45% | -0.52% | -0.42% | -0.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 1.73 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 27.15 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | -0.12 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -210.65 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 210.65 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | 0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | 0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -0.13 | -2.25 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | -1.15 | 0.00 |
| Free Cash Flow Yield | -0.00% | -0.00% | 0.00% | -0.06% | -0.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3133.70 | -221.76 | -191.48 | -236.36 | -179.69 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 2049.31 | 0.00 |
| Price-to-Book (P/B) Ratio | -14531.52 | -69.08 | -75.75 | -166.44 | -477.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -22285302.27 | -89195.54 | 26711.57 | -1777.60 | -276.12 |
| Price-to-Operating Cash Flow Ratio | -22285302.27 | -89195.54 | 26711.57 | -1777.60 | -276.12 |
| Price-to-Earnings Growth (PEG) Ratio | -2.09 | 5.54 | -7.66 | 11.82 | 2.70 |
| Enterprise Value Multiple | -18378.11 | -1258.07 | -319.82 | -237.40 | -231.57 |
| Enterprise Value | 1.85B | 7.39M | 7.44M | 7.42M | 7.40M |
| EV to EBITDA | -18378.11 | -1258.07 | -319.82 | -237.40 | -231.57 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 2058.35 | 0.00 |
| EV to Free Cash Flow | -22285302.27 | -89194.52 | 26912.53 | -1785.44 | -276.51 |
| EV to Operating Cash Flow | -22285302.27 | -89194.52 | 26912.53 | -1785.44 | -276.51 |
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Shareholders’ Equity Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 4.14 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 |
| Tax Burden | 1.27 | 1.30 | 1.66 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.29 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 9.16 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.00 | 0.00 | -0.01 | 0.13 | 0.65 |
Currency in USD
